These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 12382510)

  • 1. Vical updates Allovectin-7 melanoma program.
    Expert Rev Anticancer Ther; 2002 Oct; 2(5):481-2. PubMed ID: 12382510
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.
    Stopeck AT; Jones A; Hersh EM; Thompson JA; Finucane DM; Gutheil JC; Gonzalez R
    Clin Cancer Res; 2001 Aug; 7(8):2285-91. PubMed ID: 11489803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technology evaluation: Allovectin-7, Vical.
    Galanis E
    Curr Opin Mol Ther; 2002 Feb; 4(1):80-7. PubMed ID: 11883699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma.
    Gonzalez R; Hutchins L; Nemunaitis J; Atkins M; Schwarzenberger PO
    Melanoma Res; 2006 Dec; 16(6):521-6. PubMed ID: 17119453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanoma.
    Bergen M; Chen R; Gonzalez R
    Expert Opin Biol Ther; 2003 Apr; 3(2):377-84. PubMed ID: 12662150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic therapy targeting metastatic melanoma: allovectin-7.
    Chowdhery R; Gonzalez R
    Immunotherapy; 2011 Jan; 3(1):17-21. PubMed ID: 21174553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human gene therapy for melanoma: CT-guided interstitial injection.
    Waddill W; Wright W; Unger E; Stopeck A; Akporiaye E; Harris D; Grogan T; Schluter S; Hersh E; Stahl S
    AJR Am J Roentgenol; 1997 Jul; 169(1):63-7. PubMed ID: 9207502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Velimogene aliplasmid.
    Soares HP; Lutzky J
    Expert Opin Biol Ther; 2010 May; 10(5):841-51. PubMed ID: 20367461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical pharmacokinetics, manufacturing, and safety studies supporting a multicenter cancer gene therapy trial.
    Norman JA; Parker S; Lew D; Manthorpe M; Marquet M
    Hum Gene Ther; 1995 May; 6(5):549-50. PubMed ID: 7578391
    [No Abstract]   [Full Text] [Related]  

  • 10. Examining heterogeneity in phase II trial designs may improve success in phase III.
    Tuma RS
    J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788
    [No Abstract]   [Full Text] [Related]  

  • 11. New proposed guidelines for clinical trials in liver cancer.
    Lang L
    Gastroenterology; 2008 Jul; 135(1):7. PubMed ID: 18554512
    [No Abstract]   [Full Text] [Related]  

  • 12. Reactive oxygen species may have antitumor activity in metastatic melanoma.
    Tuma RS
    J Natl Cancer Inst; 2008 Jan; 100(1):11-2. PubMed ID: 18159075
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma.
    Doukas J; Rolland A
    Cancer Gene Ther; 2012 Dec; 19(12):811-7. PubMed ID: 23037806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Sufficient life expectancy": an amazing inclusion criterion in cancer phase II-III trials.
    Penel N; Clisant S; Lefebvre JL; Adenis A
    J Clin Oncol; 2009 Sep; 27(26):e105. PubMed ID: 19667257
    [No Abstract]   [Full Text] [Related]  

  • 15. Standardization, more funds on horizon for clinical trials.
    McNeil C
    J Natl Cancer Inst; 2005 Apr; 97(8):555-7. PubMed ID: 15840874
    [No Abstract]   [Full Text] [Related]  

  • 16. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development.
    De Ridder F
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):235-41. PubMed ID: 15733220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval.
    Goffin J; Baral S; Tu D; Nomikos D; Seymour L
    Clin Cancer Res; 2005 Aug; 11(16):5928-34. PubMed ID: 16115935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [To outwit melanoma with its own tricks].
    Bischoff A
    MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
    [No Abstract]   [Full Text] [Related]  

  • 20. Dose selection in seamless phase II/III clinical trials based on efficacy and safety.
    Kimani PK; Stallard N; Hutton JL
    Stat Med; 2009 Mar; 28(6):917-36. PubMed ID: 19152231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.